{"nctId":"NCT01705574","briefTitle":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","startDateStruct":{"date":"2012-10-24","type":"ACTUAL"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"count":583,"armGroups":[{"label":"E/C/F/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TDF","Drug: ATV Placebo","Drug: RTV Placebo","Drug: FTC/TDF Placebo"]},{"label":"ATV + RTV+ FTC/TDF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ATV","Drug: RTV","Drug: FTC/TDF","Drug: E/C/F/TDF Placebo"]},{"label":"Open-Label Extension Phase","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TDF","Drug: ATV","Drug: RTV","Drug: FTC/TDF","Drug: E/C/F/TAF"]}],"interventions":[{"name":"E/C/F/TDF","otherNames":["Stribild®"]},{"name":"ATV","otherNames":["Reyataz®"]},{"name":"RTV","otherNames":["Norvir®"]},{"name":"FTC/TDF","otherNames":["Truvada®"]},{"name":"E/C/F/TDF Placebo","otherNames":[]},{"name":"ATV Placebo","otherNames":[]},{"name":"RTV Placebo","otherNames":[]},{"name":"FTC/TDF Placebo","otherNames":[]},{"name":"E/C/F/TAF","otherNames":["Genvoya®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Female (at birth), age ≥ 18 years\n* Ability to understand and sign a written informed consent form\n* Plasma HIV-1 RNA levels ≥ 500 copies/mL\n* No prior use of any approved or investigational antiretroviral drug for any length of time\n* Screening genotype report must show sensitivity to emtricitabine (FTC), tenofovir disoproxil fumarate (TDF) and atazanavir (ATV) boosted with ritonavir (RTV)\n* Normal ECG\n* Adequate renal function: Estimated glomerular filtration rate ≥ 70 mL/min according to the Cockcroft Gault formula\n* Hepatic transaminases ≤ 5 x upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 mg/dL\n* Adequate hematologic function\n* Serum amylase ≤ 5 x ULN\n* Women of childbearing potential must agree to utilize protocol recommended contraception methods or be non-heterosexually active, or practice sexual abstinence from screening throughout the duration of the study period and for 30 days following the last dose of study drug\n* Women who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.\n\nKey Exclusion Criteria:\n\n* A new AIDS defining condition diagnosed within the 30 days\n* Females receiving drug treatment for Hepatitis C, or females who are anticipated to receive treatment for Hepatitis C during the course of the study\n* Females experiencing decompensated cirrhosis\n* Females who are breastfeeding\n* Positive serum pregnancy test (female of childbearing potential)\n* Have an implanted defibrillator or pacemaker\n* Have an ECG pulse rate interval ≥ 220 msec\n* Current alcohol or substance use which may potentially interfere with the female's study compliance\n* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma\n* Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline\n* Participation in any other clinical trial without prior approval\n* Any other clinical condition or prior therapy that would make the female unsuitable for the study or unable to comply with the dosing requirements\n* Females receiving ongoing therapy with any disallowed medications, including drugs not to be used with elvitegravir, cobicistat, FTC, TDF, ATV, RTV; or females with any known allergies to the excipients of Stribild® tablets, Truvada® tablets, atazanavir capsules or ritonavir tablets\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 of the double-blind phase was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"80.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48 of the Double-Blind Phase","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":"165.1"},{"groupId":"OG001","value":"212","spread":"176.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 for the STB Group as Determined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Receiving STB or ATV+RTV+TVD With HIV-1 RNA < 50 Copies/mL at Week 48 of the Open-Label Extension Phase","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 of the open-label phase was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null},{"groupId":"OG001","value":"86.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4+ Cell Count at Week 48 of the Open-Label Extension Phase","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":"190.4"},{"groupId":"OG001","value":"35","spread":"137.5"},{"groupId":"OG002","value":"49","spread":"204.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":289},"commonTop":["Upper respiratory tract infection","Headache","Nausea","Malaria","Neuropathy peripheral"]}}}